0001437749-20-024044.txt : 20201116 0001437749-20-024044.hdr.sgml : 20201116 20201116212112 ACCESSION NUMBER: 0001437749-20-024044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201112 FILED AS OF DATE: 20201116 DATE AS OF CHANGE: 20201116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DE GREEF RODERICK CENTRAL INDEX KEY: 0001241181 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 201319081 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2020-11-12 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001241181 DE GREEF RODERICK C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 CFO & COO Common Stock 2020-11-12 4 M 0 10000 1.76 A 166293 D Common Stock 2020-11-12 4 S 0 10000 32.10 D 156293 D Common Stock 2020-11-13 4 M 0 10000 1.76 A 166293 D Common Stock 2020-11-13 4 S 0 10000 31.87 D 156293 D Common Stock 2020-11-16 4 M 0 10000 1.76 A 166293 D Common Stock 2020-11-16 4 S 0 10000 31.33 D 156293 D Stock Option (Right to Buy) 1.76 2020-11-12 4 M 0 10000 0 D 2026-03-04 Common Stock 10000 20000 D Stock Option (Right to Buy) 1.76 2020-11-13 4 M 0 10000 0 D 2026-03-04 Common Stock 10000 10000 D Stock Option (Right to Buy) 1.76 2020-11-16 4 M 0 10000 0 D 2026-03-04 Common Stock 10000 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.76 to $32.45, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.65 to $32.28, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.75 to $31.90, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The options vested 25% on March 4, 2017 and thereafter, in 36 equal monthly installments. /s/ Roderick de Greef 2020-11-16